Abstract: The present description provides improved methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro. Also provided are isolated invitro cell populations, compositions, and systems comprising TEP cells produced in vitro. Compositions and systems of cell populations of thymic epithelial cells and subpopulations thereof, as well as cells formed during different stages of differentiation of PS cells into thymic epithelial cells and subpopulations thereof are provided.

Abstract: Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional TEP cells that mature into thymic epithelial cells in vivo.

Abstract: Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional TEP cells that mature into thymic epithelial cells in vivo.

Abstract: The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.

Abstract: The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.

Abstract: The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.

Abstract: An improved culture vessel or bioreactor for growing cells, cellular aggregates, tissue particles or tissue “organoids” and methods for using same which includes a housing having at least one chamber defined by a curved wall symmetrical about an axis. The perfused version of the vessel has at least one inlet and at least one outlet and at least one filter in fluid communication with at least one of the inlets or outlets structured to pass culture media but retain cells, cellular aggregates or tissues within the culture chamber. The batch culture version of the vessel has at least part of the vessel wall made of a gas permeable material. The vessel housing is rotated about the horizontal or proximate horizontal axis to suspend the cells, in an unobstructed, three-dimensional or toroidal flow. The chamber has a substantially ellipsoid, oblate ellipsoid, spherical or oblate spherical shape and an unobstructed volume for growth of cells, cellular aggregates or tissues.